Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 20;35:100682.
doi: 10.1016/j.nmni.2020.100682. Online ahead of print.

A Short Review on Antibody Therapy for COVID-19

Free PMC article

A Short Review on Antibody Therapy for COVID-19

Govindarajan Venkat Kumar et al. New Microbes New Infect. .
Free PMC article


The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.

Keywords: Convalescent plasma therapy; Monoclonal antibody therapy; SARS-CoV-2.

Similar articles

See all similar articles


    1. Guo Y., Cao Q., Hong Z. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Milit Med Res. 2020;7:11. - PMC - PubMed
    1. Paules C.I., Marston H.D., Fauci A.S. Coronavirus infections—more than just the common cold. JAMA. 2020;323(8):707–708. - PubMed
    1. Chowell G., Abdirizak F., Lee S. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med. 2015;13:210. - PMC - PubMed
    1. Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–137. - PMC - PubMed
    1. Andersen K.G., Rambaut A., Lipkin W.I. The proximal origin of SARS-CoV-2. Nat Med. 2020 - PMC - PubMed